High incidence of BRCA1–2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma

HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges

“…[4][5][6] Increased incidence of uterine serous carcinoma (USC) has also been linked to African American ethnicity and tamoxifen use. [7][8][9][10] Several papers suggested that BRCA gene mutations might also be associated with an increased risk of USC among Ashkenazi Jews, 9,11-13 whereas others-including a large prospective study-were unable to confirm such association either among Jews or in an unselected patient population. [14][15][16] Uterine serous carcinoma is the most biologically aggressive variant of endometrial carcinoma, with predilection for deep myometrial and lymphovascular space invasion, as well as peritoneal and distant metastatic spread.…”

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy

“…Therefore, according to some authors [10], there is little evidence to suggest the systematic performance of hysterectomy to prevent tubal carcinoma. However, hysterectomy can be taken into consideration for other reasons, such as the reduction of endometrial cancer risk associated with tamoxifen treatment for a previous breast cancer [73] or the elimination of the low risk of uterine serous papillary carcinoma [14][15][16].…”

“…The risk for this latter malignancy for BRCA2 mutation carriers is lower than for BRCA1 carriers. Also, uterine serous papillary carcinoma appears to be a BRCA1-related disease, but it can occur in only 1-2 cases per 1000 BRCA mutation carriers [14][15][16].…”

The Role of Prophylactic Oophorectomy in the Management of Hereditary Breast & Ovarian Cancer Syndrome

“…BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk of developing breast cancer, respectively and an 18-60% and 11-27% lifetime risk of developing ovarian cancer (Antoniou et al, 2003;Easton et al, 1995;King et al, 2003). Furthermore, BRCA1 mutation carriers are at increased risk for fallopian tube carcinoma (Paley et al, 2001;Zweemer et al, 2000), primary peritoneal carcinoma (Levine et al, 2003;Olivier et al, 2004), and uterine serous papillary carcinoma (Biron-shental et al, 2006). BRCA2 mutations are also associated with increased risk for a variety of other cancers including melanoma, pancreas, bone, hepatobiliary and pharyngeal cancer (Breast Cancer Linkage Consortium, 1999).…”

“…It is essential that the fallopian tube is resected as close as possible to the uterine cornua to prevent the occurrence of proximal fallopian tube malignancy. Indeed the risk of proximal fallopian tube malignancy in the uterine fundus and the low risk of uterine papillary carcinoma in BRCA1/BRCA2 mutation carriers raises the question of whether these patients should undergo concomitant hysterectomy as part of risk reducing surgery (Biron-Shental et al, 2006;Hornreich et al, 1999;Paley et al, 2001). Removal of the entire fallopian tube can be optimally accomplished by performing a hysterectomy but the majority (92%) of fallopian tube malignancies occur in the mid and distal portions of the tube (Alvarado-Cabrero et al, 1999) thus there is little evidence to support systematic hysterectomy at the time of PSO on this basis.…”